Welcome to Paid Research Studies




  • Condition:   Chordoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Chordoma
    Intervention:   Drug: Afatinib
    Sponsors:   Leiden University Medical Center;   Chordoma Foundation;   Boehringer Ingelheim
    Recruiting

  • Condition:   Chordoma
    Interventions:   Other: Randomized Cohort;   Radiation: Prospective cohort
    Sponsor:   Italian Sarcoma Group
    Recruiting

  • Condition:   Chordoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Radiation: Stereotactic Radiosurgery
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI);   Bristol-Myers Squibb;   Chordoma Foundation
    Recruiting

  • Condition:   Sacral Chordoma
    Interventions:   Radiation: protons;   Radiation: carbon ions
    Sponsor:   Heidelberg University
    Recruiting

  • Conditions:   Skull Base Chordoma;   Vertebral Chordoma
    Interventions:   Procedure: Surgery;   Radiation: Protontherapy;   Drug: 18F FAZA
    Sponsor:   Institut Curie
    Recruiting

  • Conditions:   Chordoma;   Unresectable Malignant Neoplasm
    Interventions:   Biological: Aldoxorubicin Hydrochloride;   Biological: ALT-803;   Biological: ETBX-051;   Biological: ETBX-061;   Biological: GI-6301;   Biological: haNK;   Drug: Avelumab;   Drug: Cetuximab;   Drug: Cyclophosphamide;   Radiation: SBRT
    Sponsor:   NantKwest, Inc.
    Not yet recruiting

  • Conditions:   Chordomas;   Chondrosarcomas
    Intervention:   Radiation: Proton Therapy
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Conditions:   Genes;   Sporadic Chordoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chordoma;   Locally Advanced Chordoma;   Metastatic Chordoma;   Unresectable Chordoma
    Interventions:   Biological: Nivolumab;   Biological: Relatlimab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Medulloblastoma;   Ependymoma;   Meningioma;   Chordoma;   Pineolblastoma
    Intervention:   Drug: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Sarcoma
    Interventions:   Drug: Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC];   Drug: Nivolumab IV Soln 100 MG/10ML;   Drug: Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution
    Sponsor:   Sarcoma Oncology Research Center, LLC
    Not yet recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Rhabdoid Tumors (MRT);   Rhabdoid Tumors of the Kidney (RTK);   Atypical Teratoid Rhabdoid Tumors (ATRT);   Selected Tumors With Rhabdoid Features;   Synovial Sarcoma;   INI1-negative Tumors;   Malignant Rhabdoid Tumor of Ovary;   Renal Medullary Carcinoma;   Epithelioid Sarcoma;   Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval);   Any Solid Tumor With an EZH2 GOF Mutation
    Intervention:   Drug: Tazemetostat
    Sponsor:   Epizyme, Inc.
    Recruiting